Eberhard Karls Universität Tübingen, Interfaculty Institute of Microbiology and Infection Medicine (IMIT),
Institute for Medical Microbiology and Hygiene,
University Hospital Tübingen

Full Professor, Head of the Institute for Medical Microbiology and Hygiene, Dean of the Medical Faculty; Research Group leader

University Hospital Tübingen,
Interfaculty Institute of Microbiology and Infection Medicine (IMIT),
Institute for Medical Microbiology and Hygiene
Elfriede-Aulhorn-Straße 6
72076 Tübingen

+49 7071 2982349




Background and expertise of the representative

Ingo Autenrieth is full professor and Head of the Department for Medical Microbiology and Hygiene, spokesperson of the Interfaculty Institute of Microbiology and Infection Medicine and Dean of the Medical Faculty of the University of Tübingen. Dr. Monika Schütz is an independent group leader. The groups have strong expertise in the analysis of pathogenicity mechanisms of Gram-negative pathogens, antibiotic resistance mechanisms, emergence and spread of resistance and the role of the microbiome for health, disease and as a reservoir for antibiotic resistance genes. The institute employs state-of-the art next generation sequencing methods, in-house developed NGS analysis pipelines, molecular and NGS-based diagnostics, epidemiology and molecular microbiology and computational methods (infection modelling, machine learning approaches) to understand antibiotic resistance and its emergence and spread with the ultimate aim to improve therapy of infections with resistant Gram-negative pathogens. Within the German Center of Infection Research (DZIF), Ingo Autenrieth is the speaker of the Tübingen site, has been the co-coordinator of the thematic translational unit dealing with gastrointestinal infections and infections caused by gut-derived pathogens, and is now elected member of the DZIF Executive Board.

Monika Schütz and Ingo Autenrieth are strongly involved in several DZIF-funded projects aiming at the development of new anti-infective therapies and are based on the interference with bacterial secretion systems and outer membrane biogenesis. To this end, (high-throughput) screening assays have been developed and screens were performed (one was run in collaboration with the European Lead Factory and 400.000 compounds were screened successfully). Currently, lead structures are defined and structure-activity relationships are studied. In addition, the Institute performs the microbiology diagnostics for the entire University Hospital Tübingen and has access to a comprehensive strain collection as well as associated patient data. Ingo Autenrieth has published more than 200 publications and is the co-founder of the CeMeT (Center for Metagenomics) GmbH that performs sequencing and data analysis on complex microbiome samples. Ingo Autenrieth is member of the committee of the German Association of Medical Faculties, of the curatorium of the Max-Planck-Institute for Developmental Biology Tübingen, of the committee “Forward Look” of the European Science Foundation and of the scientific committee of the Helmholtz-Center for Infection Research HZI, Braunschweig. Ingo Autenrieth was co-speaker of the Collaborative Research Centre (SFB) 766 “The Bacterial Cell Envelope: Structure, Function and Infection Interface” and has coordinated various national and international research consortia on different aspects of pathogenicity mechanisms, host-microbiome interactions and antibiotic resistance. Further, he is PI within the recently granted cluster of excellence "Control of Microorganisms to Fight Infection (CMFI)”.

Monika Schütz is an expert, highly specialized in genetics, genomics, molecular biology, proeomics and preclinical experimental animal systems, and has successfully lead several highly competitive projects in national and international research consortia and flagship projects for target development and drug screenings in Gram-negative bacteria.

Organisation profile

The Institute for Medical Microbiology and Hygiene of the University Hospital Tübingen, runs a state-of the art microbiological diagnostics department. The research carried out at the institute has a strong focus on understanding the pathogenicity mechanisms of Gram-negative pathogens, the emergence and spread of antibiotic resistance, the interaction of pathogens with the host and the microbiome, the role of the microbiome for health and disease and aims to translate the results of this research into improvement of patient treatment.

Together with Microbiology groups from the Science Faculty the Institute has founded the first joint Interfaculty Institute of Microbiology and Infection Medicine (IMIT) in Germany (2009) with the aim to comprehensively study various aspects of controlling bacterial infections while bringing together basic research, translational approaches and the clinics. Research of the Institute is financed and supported by the German Research Association (DFG), the Federal Ministry of Education and Research (BMBF), the German Center for Infection Research (DZIF), the EU, the European Lead Factory and by industrial cooperation partners. Central research initiatives of the Department include the Collaborative Research Centre „The Bacterial Cell Envelope“ (SFB 766) and various projects and clinical studies in the framework of the DZIF. Currently the Department employs ca. 130 people.

Microbiology and Infection Biology are strong core focus areas of the University Tübingen, which provides an optimal infrastructure for this type of research (e.g. Proteome Center, Quantitative Biology Center [QBiC], Tübingen Center for Academic Drug Discovery and Development [TüCAD2], NGS Competence Center Tübingen, NCCT). The University also offers advice and support in transferring the generated knowledge into cooperation projects with industry or spin-off endeavors.

Contribution to the network

Ingo Autenrieth, Monika Schütz and co-workers will participate in the network by providing his expertise in the identification of microbial pathogenicity and resistance mechanisms, NGS and analysis pipelines, and HTS assay development. His group will provide tools and techniques for the genetic manipulation of multiresistant strains, provide access to clinical isolates, NGS techniques and support the development of HTS assays.

Ingo Autenrieth will help with his manifold international and national contacts to academia and industry to strengthen the network by including additional external competence.